Healthcare Providers and Services
Company Overview of Millennium Health, LLC
Millennium Health, LLC offers clinically actionable information for the right treatment decisions for patients at the right time. The company provides medication monitoring, pharmacogenetic testing, urine drug testing (UDT), and oral fluid testing (OFT) services. Its solutions include RxAnte System, an analytics platform that includes predictive and decision analytics, advanced evaluation methods, and a cloud-based platform that equips health care professionals, such as payers, pharmacy benefit management companies, and providers to improve medication outcomes for patients at the population or individual level; Millennium UDT Rapid Assessment Drug Adherence report with graphed results; and M...
16981 Via Tazon
San Diego, CA 92127
Founded in 2007
Key Executives for Millennium Health, LLC
Founder and Chairman of The Board
General Manager of Analytics and President of RxAnte
Compensation as of Fiscal Year 2015.
Millennium Health, LLC Key Developments
Millennium Health to Provide Urine Drug Testing for a U.S. Food and Drug Administration Approved Clinical Trial
Oct 28 15
Millennium Health announced it has been selected to provide urine drug testing (UDT) for a U.S. Food and Drug Administration (FDA) approved clinical trial. Data from the trial will be used to help estimate the serious risk for the development of hyperalgesia following use of extended-release long-acting (ER/LA) opioid analgesics to treat chronic pain for at least one year. The trial will also assess the development of tolerance following use of ER/LA opioid analgesics and include an assessment of risk relative to efficacy. In September 2013, the FDA announced a series of post-marketing requirements for manufacturers of ER/LA opioid analgesic products. Nine manufacturers of these medications formed a consortium known as the Opioid Post-marketing Requirement Consortium (OPC) to carry out research aimed at understanding safe and appropriate use for chronic pain. After a rigorous review process, Millennium was selected by OPC to provide UDT services, expert consultation, and research collaboration on the clinical trial. Millennium's contract award could be valued at up to $1.6 million dollars at the completion of the clinical trial. The multicenter study is randomized, double-blind, placebo-controlled clinical trial of structured opioid discontinuation versus continued opioid therapy in suboptimal and optimal responders to high-dose, long-term opioid analgesic therapy for chronic pain. Approximately 3,280 subjects will be screened and several hundred will go on to participate.
Millennium Health to Pay $256 Million to Resolve False Claims Charge
Oct 19 15
Millennium Health has agreed to pay $256 million to resolve alleged violations of the False Claims Act for billing Medicare, Medicaid and other federal health care programs for medically unnecessary urine drug and genetic testing and for providing free items to physicians who agreed to refer expensive laboratory testing business to Millennium. Millennium has agreed to pay $227 million to resolve False Claims Act allegations, detailed in a complaint filed by the United States, that Millennium systematically billed federal health care programs for excessive and unnecessary urine drug testing from Jan. 1, 2008, through May 20, 2015. The United States alleged that Millennium caused physicians to order excessive numbers of urine drug tests, in part through the promotion of "custom profiles," which, instead of being tailored to individual patients, were in effect standing orders that caused physicians to order large number of tests without an individualized assessment of each patient's needs. Millennium has also agreed to pay $10 million to resolve False Claims Act allegations that it submitted false claims to federal health care programs from Jan. 1, 2012, through May 20, 2015, for genetic testing that was performed routinely and without an individualized assessment of need. In connection with the False Claims Act settlements, Millennium has also entered into a corporate integrity agreement (CIA) with the Department of Health and Human Services-Office of Inspector General (HHS-OIG). In addition, Millennium will pay $19.2 million to the Centers for Medicare and Medicaid Services (CMS) to resolve certain administrative actions related to Millennium's urine drug test billing practices.
Millennium Health Finalizes Settlement Agreement with DOJ
Oct 16 15
Millennium Health announced that it has reached agreement with a substantial majority of holders of its debt, its current equity holders, the Department of Justice (DOJ), the Centers for Medicare & Medicaid Services (CMS) and other state and federal agencies, on the terms of a financial restructuring plan that would satisfy a previously announced settlement and reduce the company's debt. The previously announced proposed settlement with the DOJ resolves federal and state claims involving the Company. The company intends to begin soliciting formal votes on a restructuring plan from its lenders in the coming weeks. The restructuring support agreement approved on October 16, 2015 allows the Company to execute its restructuring on either an out-of-court basis or through a prepackaged Chapter 11 proceeding that primarily affects the claims of lenders and equity holders. The entire restructuring proceeding is expected to be concluded by year end.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|